299 related articles for article (PubMed ID: 24402925)
1. PD-1 inhibitors raise survival in NSCLC.
Cancer Discov; 2014 Jan; 4(1):6. PubMed ID: 24402925
[TBL] [Abstract][Full Text] [Related]
2. PD-1 Blockers.
Wolchok JD
Cell; 2015 Aug; 162(5):937. PubMed ID: 26317459
[TBL] [Abstract][Full Text] [Related]
3. Comparison between PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab, and atezolizumab) in pretreated NSCLC patients: Evidence from a Bayesian network model.
Wu Y; Lin L; Shen Y; Wu H
Int J Cancer; 2018 Dec; 143(11):3038-3040. PubMed ID: 29987914
[No Abstract] [Full Text] [Related]
4. Nivolumab: a review in advanced squamous non-small cell lung cancer.
Keating GM
Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
[TBL] [Abstract][Full Text] [Related]
5. Clinical Trials of PD-1 and PD-L1 inhibitors in NSCLC.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):14-6. PubMed ID: 24852398
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of PD-1 inhibitors in non-small cell lung cancer patients positive for antinuclear antibodies.
Yoneshima Y; Tanaka K; Shiraishi Y; Hata K; Watanabe H; Harada T; Otsubo K; Iwama E; Inoue H; Masuda S; Nakanishi Y; Okamoto I
Lung Cancer; 2019 Apr; 130():5-9. PubMed ID: 30885351
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer.
Morgensztern D; Herbst RS
Clin Cancer Res; 2016 Aug; 22(15):3713-7. PubMed ID: 27252413
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab for advanced squamous cell lung cancer: what are the next steps?
de Mello RA; Pousa I; Pereira D
Lancet Oncol; 2015 Mar; 16(3):234-5. PubMed ID: 25704436
[No Abstract] [Full Text] [Related]
9. Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.
Pellegrino B; Musolino A; Tiseo M
Ann Oncol; 2017 Jun; 28(6):1405-1406. PubMed ID: 28383638
[No Abstract] [Full Text] [Related]
10. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
11. The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C; Besse B; Brahmer JR; Crinò L; Felip E; de Marinis F
Clin Lung Cancer; 2016 May; 17(3):161-8. PubMed ID: 26908078
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
Ulmeanu R; Antohe I; Anisie E; Antoniu S
Expert Rev Anticancer Ther; 2016; 16(2):165-7. PubMed ID: 26634873
[TBL] [Abstract][Full Text] [Related]
13. The "value" of immune-checkpoint inhibitors for advanced lung cancer.
Inoue A
Respir Investig; 2017 Jul; 55(4):253-254. PubMed ID: 28705302
[No Abstract] [Full Text] [Related]
14. Immunotherapy for lung cancer: Targeting the PD-1 pathway.
Vafadar S
JAAPA; 2017 Jun; 30(6):48-50. PubMed ID: 28538431
[TBL] [Abstract][Full Text] [Related]
15. More Benefits for Checkpoint Inhibitors in NSCLC.
Cancer Discov; 2015 Dec; 5(12):OF2. PubMed ID: 26511141
[TBL] [Abstract][Full Text] [Related]
16. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.
Gettinger S; Herbst RS
Cancer J; 2014; 20(4):281-9. PubMed ID: 25098289
[TBL] [Abstract][Full Text] [Related]
17. [Biological follow-up of patients with HIV treated with anti-PD-1 or anti-PD-L1 for non-small cell bronchial carcinoma: A task group proposal].
Guihot A; Cadranel J; Lambotte O; Lavolé A; Autran B; Spano JP
Rev Mal Respir; 2016 Jun; 33(6):419-21. PubMed ID: 27140903
[No Abstract] [Full Text] [Related]
18. [Immunotherapy in lung cancer: checkpoint inhibitors].
Wehler T; Wehler B; Stehle I
Dtsch Med Wochenschr; 2015 Dec; 140(24):1835-8. PubMed ID: 26625234
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab: targeting PD-1 to bolster antitumor immunity.
Brahmer JR; Hammers H; Lipson EJ
Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy drug improves survival of patients with squamous non-small cell lung cancer.
Printz C
Cancer; 2015 Oct; 121(20):3562-3. PubMed ID: 26431439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
